Meeting Report

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Non–Small Cell Lung Cancer

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

MD Anderson Cancer Center


J Adv Pract Oncol 2019;10(6):576-583 | https://doi.org/10.6004/jadpro.2019.10.6.7 | © 2019 Harborside™


  

ABSTRACT

Options for patients with non–small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center reviews the major abstracts from the 2019 ASCO Annual Meeting using coverage by The ASCO Post and offers considerations for advanced practitioners in this field.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.